Nucresiran

Highest phase reached
Phase 2
www.ebi.ac.uk
Drug type
Oligonucleotide
www.ebi.ac.uk

Listing at source
Listed
Highest phase reached
Phase 2
www.ebi.ac.uk

Drug type
Oligonucleotide
www.ebi.ac.uk
Drug name
Nucresiran
www.ebi.ac.uk

  • all p ambo 2 o methyl p thiocytidylyl 3 5 2 o methyl pthioadenylyl 3 5 2 o methyladenylyl 3 5 2 o methylguanylyl 3 5 2 o methyladenylyl 3 5 2 o methylguanylyl 3 5 2 deoxy 2 fluorouridylyl 3 5 2 o methyladenylyl 3 5 2 deoxy 2 fluorouridylyl 3 5 2 deoxy 2 fluorouridylyl 3 5 2 deoxy 2 fluorocytidylyl 3 5 2 o methylcytidylyl 3 5 2 omethyladenylyl 3 5 2 o methyluridylyl 3 5 2 o methyluridylyl 3 5 2 o methyluridylyl 3 5 2 o methyluridylyl 3 5 2 omethyluridylyl 3 5 2 o methyladenylyl 3 5 2 omethylcytidylyl 3 5 3 o 2s 4r 1 1 2 acetamido 2 deoxy β d galactopyranosyl oxy 16 16 bis 3 3 5 2 acetamido 2 deoxy β d galactopyranosyl oxy pentanamido propyl amino 3 oxopropoxy methyl 5 11 18 trioxo 14 oxa 6 10 17 triazanonacosan 29 oyl 4 hydroxypyrrolidin 2 yl methoxy hydroxy phosphoryl 2 omethyluridine duplex with all p ambo 2 o methyl p thiouridylyl 5 3 2 o methyl pthioguanylyl 5 3 2 o methylguanylyl 5 3 2 o methyluridylyl 5 3 2 o methyluridylyl 5 3 2 o methylcytidylyl 5 3 2 o methyluridylyl 5 3 2 deoxy 2 fluorocytidylyl 5 3 2 o methyladenylyl 5 3 2 deoxy 2 fluorouridylyl 5 3 2 o methyladenylyl 5 3 2 omethyladenylyl 5 3 2 o methylguanylyl 5 3 2 o methylguanylyl 5 3 2 o methyluridylyl 5 3 2 o methyladenylyl 5 3 2 omethyladenylyl 5 3 2 deoxy 2 fluoroadenylyl 5 3 2 omethyladenylyl 5 3 2 o methyladenylyl 5 3 2 o methyl pthiouridylyl 5 3 2 deoxy 2 fluoro p thioguanylyl 5 3 2 omethyladenosine
  • all-P-ambo-2'-O-methyl-P-thiocytidylyl-(3'→5')-2'-O-methyl-Pthioadenylyl-( 3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-O-methylguanylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-O-methyladenylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-deoxy-2'-fluorouridylyl-(3'→5')-2'-deoxy-2'-fluorocytidylyl-(3'→5')-2'-O-methylcytidylyl-(3'→5')-2'-Omethyladenylyl-( 3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-O-methyluridylyl-(3'→5')-2'-Omethyluridylyl-( 3'→5')-2'-O-methyladenylyl-(3'→5')-2'-Omethylcytidylyl-( 3'→5')-3'-O-[{[(2S,4R)-1-{1-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-16,16-bis({3-[(3-{5-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]pentanamido}propyl)amino]-3-oxopropoxy}methyl)-5,11,18-trioxo-14-oxa-6,10,17-triazanonacosan-29-oyl}-4-hydroxypyrrolidin-2-yl]methoxy}(hydroxy)phosphoryl]-2'-Omethyluridine duplex with all-P-ambo-2'-O-methyl-P-thiouridylyl-(5'→3')-2'-O-methyl-Pthioguanylyl-( 5'→3')-2'-O-methylguanylyl-(5'→3')-2'-O-methyluridylyl-(5'→3')-2'-O-methyluridylyl-(5'→3')-2'-O-methylcytidylyl-(5'→3')-2'-O-methyluridylyl-(5'→3')-2'-deoxy-2'-fluorocytidylyl-(5'→3')-2'-O-methyladenylyl-(5'→3')-2'-deoxy-2'-fluorouridylyl-(5'→3')-2'-O-methyladenylyl-(5'→3')-2'-Omethyladenylyl-( 5'→3')-2'-O-methylguanylyl-(5'→3')-2'-O-methylguanylyl-(5'→3')-2'-O-methyluridylyl-(5'→3')-2'-O-methyladenylyl-(5'→3')-2'-Omethyladenylyl-( 5'→3')-2'-deoxy-2'-fluoroadenylyl-(5'→3')-2'-Omethyladenylyl-( 5'→3')-2'-O-methyladenylyl-(5'→3')-2'-O-methyl-Pthiouridylyl-( 5'→3')-2'-deoxy-2'-fluoro-P-thioguanylyl-(5'→3')-2'-Omethyladenosine
  • nucresiran
  • Nucresiran
  • nucresiran [INN]
  • nucresiran inn
  • rna am sp 2 deoxy 2 fluoro g sp um am am 2 deoxy 2 fluoro a am am um gm gm am am 2 deoxy 2 fluoro u am 2 deoxy 2 fluoro c um cm um um gm sp gm sp um complex with rna cm sp am sp am gm am gm 2 deoxy 2 fluoro u am 2 deoxy 2 fluoro u 2 deoxy 2 fluoro u 2 deoxy 2 fluoro c cm am um um um um um am cm um 3 2s 4r 1 29 2 acetylamino 2 deoxy β d galactopyranosyl oxy 14 14 bis 3 3 5 2 acetylamino 2 deoxy β d galactopyranosyl oxy 1 oxopentyl amino propyl amino 3 oxopropoxy methyl 1 12 19 25 tetraoxo 16 oxa 13 20 24 triazanonacos 1 yl 4 hydroxy 2 pyrrolidinyl methyl hydrogen phosphate 1 1
  • RNA, (Am-sp-(2′-deoxy-2′-fluoro)G-sp-Um-Am-Am-(2′-deoxy-2′-fluoro)A-Am-Am-Um-Gm-Gm-Am-Am-(2′-deoxy-2′-fluoro)U-Am-(2′-deoxy-2′-fluoro)C-Um-Cm-Um-Um-Gm-sp-Gm-sp-Um), complex with RNA (Cm-sp-Am-sp-Am-Gm-Am-Gm-(2′-deoxy-2′-fluoro)U-Am-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)C-Cm-Am-Um-Um-Um-Um-Um-Am-Cm-Um) 3′-[[(2S,4R)-1-[29-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-14,14-bis[[3-[[3-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]-1,12,19,25-tetraoxo-16-oxa-13,20,24-triazanonacos-1-yl]-4-hydroxy-2-pyrrolidinyl]methyl hydrogen phosphate] (1:1)

CAS registry numbers
  • 2847913-45-3
ChEMBL ID
CHEMBL6068150
www.ebi.ac.uk
FDA ingredient codes (UNII)
  • MCT9H26JQY

First in class
No
Orphan designation
No

Prodrug
No
Chirality
Single enantiomer
Inorganic
No
Natural product
No

Sequences

  • Component
    Sequence
    Type
    Nucleic Acid
    Sequence
    (3'-5')C=A=A-G-A-U-A-U-U-C-C-A-U-U-U-U-U-A-C-U-R (5'-3')U=G=G-U-U-C-U-C-A-U-A-A-G-G-U-A-A-A-A-A-U=G=A

Related records

Trials (2)